Kyverna Therapeutics (KYTX) Expected to Announce Earnings on Monday

Key Points

• Kyverna Therapeutics is set to release its Q2 2025 earnings report on August 11, with analysts predicting a loss of ($1.00) per share.
• The company's stock recently opened at $3.41 and has a market capitalization of $147.55 million, with a significant trading beta of 3.04.
• HC Wainwright has upgraded Kyverna Therapeutics to a buy rating with a price target increase from $4.00 to $5.00, reflecting positive sentiment from multiple analysts.

Kyverna Therapeutics (NASDAQ:KYTX - Get Free Report) will likely be posting its Q2 2025 quarterly earnings results before the market opens on Monday, August 11th. Analysts expect Kyverna Therapeutics to post earnings of ($1.00) per share for the quarter.

Kyverna Therapeutics (NASDAQ:KYTX - Get Free Report) last issued its quarterly earnings data on Tuesday, May 13th. The company reported ($1.03) earnings per share for the quarter, beating analysts' consensus estimates of ($1.21) by $0.18. On average, analysts expect Kyverna Therapeutics to post $-3 EPS for the current fiscal year and $-4 EPS for the next fiscal year.

Kyverna Therapeutics Trading Down 0.8%

Shares of NASDAQ:KYTX opened at $3.41 on Monday. Kyverna Therapeutics has a 1-year low of $1.78 and a 1-year high of $8.78. The firm has a market capitalization of $147.55 million, a PE ratio of -1.01 and a beta of 3.04. The business's 50 day moving average is $3.32 and its 200-day moving average is $2.79.

Hedge Funds Weigh In On Kyverna Therapeutics

Several institutional investors have recently bought and sold shares of the business. Rhumbline Advisers raised its position in shares of Kyverna Therapeutics by 22.0% during the first quarter. Rhumbline Advisers now owns 31,614 shares of the company's stock worth $61,000 after acquiring an additional 5,694 shares during the last quarter. AQR Capital Management LLC acquired a new stake in shares of Kyverna Therapeutics during the first quarter worth $137,000. Cubist Systematic Strategies LLC grew its stake in shares of Kyverna Therapeutics by 31.1% during the first quarter. Cubist Systematic Strategies LLC now owns 68,628 shares of the company's stock worth $132,000 after purchasing an additional 16,267 shares during the period. Finally, Bank of America Corp DE grew its stake in shares of Kyverna Therapeutics by 41.6% during the fourth quarter. Bank of America Corp DE now owns 21,788 shares of the company's stock worth $81,000 after purchasing an additional 6,400 shares during the period. Institutional investors own 18.08% of the company's stock.

Wall Street Analyst Weigh In

Separately, HC Wainwright raised Kyverna Therapeutics from a "neutral" rating to a "buy" rating and lifted their price objective for the stock from $4.00 to $5.00 in a report on Tuesday, May 27th. Five analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of "Buy" and an average target price of $15.60.

Kyverna Therapeutics Company Profile

Kyverna Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing cell therapies for patients suffering from autoimmune diseases. Its lead product candidate is KYV-101, an autologous CD19 CAR T-cell product candidate for the treatment of patients with lupus nephritis and systemic sclerosis that is in Phase I clinical trial; and for myasthenia gravis and multiple sclerosis that is in Phase II clinical trial.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.